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Introduction: Acinetobacter baumannii is a Gram-negative bacteria and a significant nosocomial pathogen in
hospitals. Multidrug-resistant A. baumannii have emerged as a cause of nosocomial infections in critically ill patients.
This microorganism has the ability to produce biofilms on different surfaces, which could explain their ability to
persist in clinical environments and their role in device-related infections.
Case presentation: We present the case of a 33-year-old Hispanic man with local invasive retroperitoneal
leiomyosarcoma and right kidney exclusion along with femoral venous thrombosis, who was admitted for tumor
resection. He had been receiving multiple nephrotoxic antibiotics for a long time (including tigecycline and
colistimethate sodium) and had a persistent urinary infection related to multidrug-resistant A. baumannii (with
susceptibility to colistimethate). Colistimethate was administered through a three-lumen urinary device for
continuous urinary irrigation over seven days. Our patient did not refer to any adverse effects. A urine culture
control taken at the end of the irrigation and another taken 10 days later were negative.
Conclusion: Colistimethate sodium and other antimicrobials infused by urinary irrigation can be a good option in
patients in whom parenteral administration could be toxic.Introduction
Multidrug-resistant (MDR) Acinetobacter baumannii
has become an emergent pathogen for critically ill
patients in intensive care units in the last decade, cau-
sing ventilator-associated pneumonia, bacteremia, urinary
tract infections (UTIs) and surgical-site infections [1-3].
These microorganisms have the potential to produce bio-
films on different surfaces, which could explain their abi-
lity to persist in clinical environments and their role in
device-related infections [4]. The lack of new antibiotics
with activity against these MDR strains has obliged infec-
tious disease physicians to use older antibiotics, such as
colistimethate [5,6]. Pharmacological knowledge of this
old antibiotic remains limited because it was developed
in the 1960s, prior to the establishment of current
drug-development requirements, but it has known po-
tential for nephro- and neurotoxicity, although inhaled* Correspondence: patcornejo@yahoo.com
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distribution, and reproduction in any mediumand intraventricular administration has been described as
useful [1]. Despite the frequency of UTIs caused by MDR
A. baumannii, no information related to therapeutical
intravesical colistimethate administration was found in
the literature.
We present the case of a patient with a UTI caused by
MDR A. baumannii, who was successfully treated with
intravesical colistimethate.
Case presentation
A 33-year-old Hispanic man with local invasive retro-
peritoneal leiomyosarcoma and right kidney exclusion
along with femoral venous thrombosis was admitted
for tumor resection. A vascular graft was performed
during the surgery but our patient developed hypovol-
emic shock and acute renal failure in the immediate
postoperative period and was acutely ill when admit-
ted to the intensive care unit. He developed abdom-
inal sepsis with isolation of MDR A. baumannii,
vancomycin-resistant Enterococcus faecium and oxacillin-
resistant Staphylococcus aureus. He received meropenem,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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clinical improvement but an increase in his serum creatin-
ine level (1.9 mg/dL).
Eight days after the antimicrobials were withdrawn,
A. baumannii was isolated from a bronchial aspirate.
The patient had no fever and his chest X-ray was reported
as normal. No antimicrobial therapy was started. Ten days
later, he developed fever; MDR A. baumannii was isolated
from his urine. Tigecycline was prescribed for 10 days and
his symptoms resolved.
The patient was discharged after a 52-day hospital stay
without an indwelling urethral catheter, 10 days after
tigecycline withdrawal. Twelve days after his hospital
discharge, he developed fever, dysuria and muddy urine.
A microscopic analysis of his urine sediment showed py-
uria and nitrates. MDR A. baumannii with susceptibility
to colistimethate was isolated from his urine culture. A
UTI was diagnosed according to the Centers for Disease
Control and Prevention/National Healthcare Safety Net-
work surveillance criteria [7]. All blood cultures were
negative, and he did not have any surgical-site infections
or decubitus ulcers.
We considered intravesical administration of colisti-
methate to spare his renal function because our patient
had only one functional kidney and had received multiple
nephrotoxic drugs. Colistimethate sodium (ColmesdantW,
Stendhal Labs) 3.5 mg/kg was dissolved in a 500 cm3 sa-
line solution for 12 h and administered through a triple
intravesical catheter with continuous irrigation over seven
days. The patient’s creatinine and ureic nitrogen at this
point were 0.99 mg/dL and 8.1 mg/dL, respectively.
His urinary symptoms disappeared 48 h after starting
the intravesical irrigation. He did not report any adverse
effects while under treatment. Microscopic analysis of
the urinary sediment was negative and urine cultures
taken at the end of the irrigation, 10 days later and one
month later were all negative.
Conclusion
In our case, continuous intravesical administration of
colistimethate over seven days proved useful to eradicate
a MDR A. baumannii urinary infection. Colistimethate
administered by urinary irrigation can be a good option
in selected patients in whom parenteral administration
could be toxic.
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